BRAINLIFE.ORG





Current Neuro-Oncology




Volume 26 Number 3
15 February 2024




Home > Publications > Current Neuro-Oncology > Volume 26, Year 2024 > Number 3, 15 February






Fang CH, Wen C, Yang B, Song YH, Liu HQ, Tian L, Chen H, Bao N.
Development and validation of a nomogram and risk stratification system to predict overall survival after surgical repair for pediatric patients with medulloblastoma based on easily accessible variables.
Eur Rev Med Pharmacol Sci. 2024 Feb;28(3):969-980. doi: 10.26355/eurrev_202402_35363. PMID: 38375704. Observational study. ˍ




Martín-Fernández J, Moritz-Gasser S, Herbet G, Duffau H.
Is intraoperative mapping of music performance mandatory to preserve skills in professional musicians? Awake surgery for lower-grade glioma conducted from a meta-networking perspective.
Neurosurg Focus. 2024 Feb;56(2):E9. doi: 10.3171/2023.11.FOCUS23702. PMID: 38301246. Case report. ˍ




Driscoll RK, Lyne SB, Voce DJ, Maraka S, Gondi V, Chmura SJ, Dixit KS, Kumthekar PU, Karrison TG, Pytel P, Collins JM, Stupp R, Merrell RT, Lukas RV, Yamini B.
A multi-institutional phase I study of acetazolamide with temozolomide in adults with newly diagnosed MGMT-methylated malignant glioma.
Neurooncol Adv. 2024 Feb 1;6(1):vdae014. doi: 10.1093/noajnl/vdae014. PMID: 38420615. Interventional study. ˍ




Sanada T, Kinoshita M, Sasaki T, Yamamoto S, Fujikawa S, Fukuyama S, Hayashi N, Fukai J, Okita Y, Nonaka M, Uda T, Arita H, Mori K, Ishibashi K, Takano K, Nishida N, Shofuda T, Yoshioka E, Kanematsu D, Tanino M, Kodama Y, Mano M, Kanemura Y.
Prediction of MGMT promotor methylation status in glioblastoma by contrast-enhanced T1-weighted intensity image.
Neurooncol Adv. 2024 Feb 1;6(1):vdae016. doi: 10.1093/noajnl/vdae016. PMID: 38410136. Observational study. ˍ




Yang X, Yan X, Lu Y, Xu Y, Yang L, Li J, Miao W.
Nomogram to Predict the Prognosis of Oligodendroglioma Patients Undergoing Postoperative Adjuvant Chemotherapy.
World Neurosurg. 2024 Feb 1:S1878-8750(24)00142-6. doi: 10.1016/j.wneu.2024.01.120. PMID: 38296045. Observational study˰ ˍ




*Boschert T, Kromer K, Lerner T, Lindner K, Haltenhof G, Tan CL, Jähne K, Poschke I, Bunse L, Eisele P, Grassl N, Mildenberger I, Sahm K, Platten M, Lindner JM, Green EW.
H3K27M neoepitope vaccination in diffuse midline glioma induces B and T cell responses across diverse HLA loci of a recovered patient.
Sci Adv. 2024 Feb 2;10(5):eadi9091. doi: 10.1126/sciadv.adi9091. PMID: 38306431. Case report. ˍ
RELATED ARTICLE
Vincent CA, Remeseiro S.
The immune response behind peptide vaccination in diffuse midline glioma.
Mol Oncol. 2024 Jun 16. doi: 10.1002/1878-0261.13686. PMID: 38880657. Comment. ˍ




Perez JL, Naylor RM, Bauman MMJ, Harrison DJ, Knowles K, Burns TC, Lanzino G, Link MJ, Peris Celda M, Meyer FB, Van Gompel J, Parney IF.
Safety of the immediate use of nonsteroidal anti-inflammatory drugs after adult craniotomy for tumor.
J Neurosurg. 2024 Feb 2:1-6. doi: 10.3171/2023.11.JNS231600. PMID: 38306640. Observational study˰ ˍ




Salameh LJ, Bitzenhofer SH, Hanganu-Opatz IL, Dutschmann M, Egger V.
Blood pressure pulsations modulate central neuronal activity via mechanosensitive ion channels.
Science. 2024 Feb 2;383(6682):eadk8511. doi: 10.1126/science.adk8511. PMID: 38301001. Laboratory investigation˰˰ ˍ ˍ




Shimoi T, Sunami K, Tahara M, Nishiwaki S, Tanaka S, Baba E, Kanai M, Kinoshita I, Shirota H, Hayashi H, Nishida N, Kubo T, Mamesaya N, Ando Y, Okita N, Shibata T, Nakamura K, Yamamoto N.
Dabrafenib and trametinib administration in patients with BRAF V600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial.
EClinicalMedicine. 2024 Feb 2;69:102447. doi: 10.1016/j.eclinm.2024.102447. PMID: 38333370. Interventional study. ˍ




Zechel C, Loy M, Wegner C, Dahlke E, Soetje B, Baehr L, Leppert J, Ostermaier JJ, Lueg T, Nielsen J, Elßner J, Willeke V, Marzahl S, Tronnier V, Madany Mamlouk A.
Molecular signature of stem-like glioma cells (SLGCs) from human glioblastoma and gliosarcoma.
PLoS One. 2024 Feb 2;19(2):e0291368. doi: 10.1371/journal.pone.0291368. PMID: 38306361. Laboratory investigation. ˍ




Zhang K, Yang T, Xia Y, Guo X, Chen W, Wang L, Li J, Wu J, Xiao Z, Zhang X, Jiang W, Xu D, Guo S, Wang Y, Shi Y, Liu D, Li Y, Wang Y, Xing H, Liang T, Niu P, Wang H, Liu Q, Jin S, Qu T, Li H, Zhang Y, Ma W, Wang Y.
Molecular Determinants of Neurocognitive Deficits in Glioma: Based on 2021 WHO Classification.
J Mol Neurosci. 2024 Feb 5;74(1):17. doi: 10.1007/s12031-023-02173-4. PMID: 38315329. Observational study. ˍ




Bušić M, Rumboldt Z, Čerina D, Bušić Ž, Dolić K.
Prognostic Value of Apparent Diffusion Coefficient (ADC) in Patients with Diffuse Gliomas.
Cancers (Basel). 2024 Feb 6;16(4):681. doi: 10.3390/cancers16040681. PMID: 38398073. Observational study. ˍ




Duchatel RJ, Jackson ER, Parackal SG, Kiltschewskij D, Findlay IJ, Mannan A, Staudt DE, Thomas BC, Germon ZP, Laternser S, Kearney PS, Jamaluddin MFB, Douglas AM, Beitaki T, McEwen HP, Persson ML, Hocke EA, Jain V, Aksu M, Manning EE, Murray HC, Verrills NM, Sun CX, Daniel P, Vilain RE, Skerrett-Byrne DA, Nixon B, Hua S, de Bock CE, Colino-Sanguino Y, Valdes-Mora F, Tsoli M, Ziegler DS, Cairns MJ, Raabe EH, Vitanza NA, Hulleman E, Phoenix TN, Koschmann C, Alvaro F, Dayas CV, Tinkle CL, Wheeler H, Whittle JR, Eisenstat DD, Firestein R, Mueller S, Valvi S, Hansford JR, Ashley DM, Gregory SG, Kilburn LB, Nazarian J, Cain JE, Dun MD.
PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.
J Clin Invest. 2024 Feb 6;134(6):e170329. doi: 10.1172/JCI170329. PMID: 38319732. Laboratory investigation. ˍ
RELATED ARTICLE
Tzaridis T, Wechsler-Reya RJ.
Just a spoonful of metformin helps the medicine go down.
J Clin Invest. 2024 Mar 15;134(6):e179144. doi: 10.1172/JCI179144. PMID: 38488006. Comment. ˍ




Chen Y, Ma J, Gao Q, Gai Y, Sun Y, Wang M.
Larotrectinib versus infigratinib for adult patients with both glioma and tyrosine kinase alterations after failure of initial therapies: Efficacy and safety analysis.
Clinics (Sao Paulo). 2024 Feb 7;79:100329. doi: 10.1016/j.clinsp.2024.100329. PMID: 38330791. Observational study. ˍ




Keric N, Krenzlin H, Kalasauskas D, Freyschlag CF, Schnell O, Misch M, von der Brelie C, Gempt J, Krigers A, Wagner A, Lange F, Mielke D, Sommer C, Brockmann MA, Meyer B, Rohde V, Vajkoczy P, Beck J, Thomé C, Ringel F.
Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
J Neurooncol. 2024 Feb 7. doi: 10.1007/s11060-024-04585-7. PMID: 38326661. Observational study. ˍ




Mani S, Chatterjee A, Dasgupta A, Shirsat N, Pawar A, Epari S, Sahay A, Sahu A, Moiyadi A, Prasad M, Chinnaswamy G, Gupta T.
Clinico-Radiological Outcomes in WNT-Subgroup Medulloblastoma.
Diagnostics (Basel). 2024 Feb 7;14(4):358. doi: 10.3390/diagnostics14040358. PMID: 38396397. Observational study. ˍ




Nabors LB, Lamb LS, Goswami T, Rochlin K, Youngblood SL.
Adoptive cell therapy for high grade gliomas using simultaneous temozolomide and intracranial mgmt-modified γδ t cells following standard post-resection chemotherapy and radiotherapy: current strategy and future directions.
Front Immunol. 2024 Feb 7;15:1299044. doi: 10.3389/fimmu.2024.1299044. PMID: 38384458. Interventional study; Perspective. ˍ




Trkova K, Sumerauer D, Bubenikova A, Krskova L, Vicha A, Koblizek M, Zamecnik J, Jurasek B, Kyncl M, Malinova B, Ondrova B, Jones DTW, Sill M, Strnadova M, Stolova L, Misove A, Benes V 3rd, Zapotocky M.
Clinical and molecular study of radiation-induced gliomas.
Sci Rep. 2024 Feb 7;14(1):3118. doi: 10.1038/s41598-024-53434-0. PMID: 38326438. Observational study. ˍ




*Briceno N, Vera E, Komlodi-Pasztor E, Abdullaev Z, Choi A, Grajkowska E, Kunst T, Levine J, Lindsley M, Fernandez K, Reyes J, Boris L, Burton E, Panzer M, Polskin L, Penas-Prado M, Pillai T, Theeler BJ, Wu J, Wall K, Papanicolau-Sengos A, Quezado M, Smirniotopoulos J, Aldape K, Armstrong TS, Gilbert MR.
Long-term survivors of glioblastoma: Tumor molecular, clinical, and imaging findings.
Neurooncol Adv. 2024 Feb 8;6(1):vdae019. doi: 10.1093/noajnl/vdae019. PMID: 38420614. Observational study. ˍ




Alhalabi OT, Dao Trong P, Kaes M, Jakobs M, Kessler T, Oehler H, König L, Eichkorn T, Sahm F, Debus J, von Deimling A, Wick W, Wick A, Krieg SM, Unterberg AW, Jungk C.
Repeat surgery of recurrent glioma for molecularly informed treatment in the age of precision oncology: A risk-benefit analysis.
J Neurooncol. 2024 Feb 9. doi: 10.1007/s11060-024-04595-5. PMID: 38334907. Observational study. ˍ




Arrillaga-Romany I, Gardner SL, Odia Y, Aguilera D, Allen JE, Batchelor T, Butowski N, Chen C, Cloughesy T, Cluster A, de Groot J, Dixit KS, Graber JJ, Haggiagi AM, Harrison RA, Kheradpour A, Kilburn L, Kurz SC, Lu G, MacDonald TJ, Mehta M, Melemed AS, Nghiemphu PL, Ramage SC, Shonka N, Sumrall A, Tarapore R, Taylor L, Umemura Y, Wen PY.
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
J Clin Oncol. 2024 Feb 9:JCO2301134. doi: 10.1200/JCO.23.01134. PMID: 38335473. Interventional study. ˍ




Chen Y, Buchanan P, Brossier NM, Navalkele P.
Incidence and survival characteristics of pediatric ganglioglioma from 2004 to 2018, with focus on infratentorial sites.
Neurooncol Pract. 2024 Feb 9;11(3):328-335. doi: 10.1093/nop/npae012. PMID: 38737603. Observational study˰ ˍ




Robinson JW, Martin R, Ozawa M, Elwenspoek MMC, Redaniel MT, Kurian K, Ben-Shlomo Y.
Use of drugs for hyperlipidaemia and diabetes and risk of primary and secondary brain tumours: nested case-control studies using the UK Clinical Practice Research Datalink (CPRD).
BMJ Open. 2024 Feb 9;14(2):e072026. doi: 10.1136/bmjopen-2023-072026. PMID: 38336454. Observational study. ˍ




Röttgering JG, Taylor JW, Brie M, Luks T, Hervey-Jumper SL, Phan S, Bracci PM, Smith E, De Witt Hamer PC, Douw L, Weyer-Jamora C, Klein M.
Understanding the association between fatigue and neurocognitive functioning in patients with glioma: A cross-sectional multinational study.
Neurooncol Pract. 2024 Feb 9;11(3):284-295. doi: 10.1093/nop/npae011. PMID: 38737609. Observational study. ˍ




Shah K, Bhartia V, Biswas C, Sahu A, Shetty PM, Singh V, Velayutham P, Awate SP, Moiyadi AV.
Tumor location and neurocognitive function-Unravelling the association and identifying relevant anatomical substrates in intra-axial brain tumors.
Neurooncol Adv. 2024 Feb 9;6(1):vdae020. doi: 10.1093/noajnl/vdae020. PMID: 38464948. Observational study. ˍ




*Ji J, Ding K, Cheng B, Zhang X, Luo T, Huang B, Yu H, Chen Y, Xu X, Lin H, Zhou J, Wang T, Jin M, Liu A, Yan D, Liu F, Wang C, Chen J, Yan F, Wang L, Zhang J, Yan S, Wang J, Li X, Chen G.
Radiotherapy-Induced Astrocyte Senescence Promotes an Immunosuppressive Microenvironment in Glioblastoma to Facilitate Tumor Regrowth.
Adv Sci (Weinh). 2024 Feb 11:e2304609. doi: 10.1002/advs.202304609. PMID: 38342629. Laboratory investigation. ˍ




Traunwieser T, Loos E, Ottensmeier H, Gastberger K, Nemes K, Mynarek M, Bison B, Kandels D, Neumayer P, Neumann-Holbeck A, Lüttich P, Baust K, Faulstich-Ritter K, John R, Kreisch A, Landmann J, Manteufel E, Nest A, Prüfe J, Schubert L, Stamm W, Timmermann B, Gerss J, Rutkowski S, Schlegel PG, Eyrich M, Gnekow AK, Frühwald MC.
Survivors of infant atypical teratoid/rhabdoid tumors present with severely impaired cognitive functions especially for fluid intelligence and visual processing: data from the German brain tumor studies.
Pediatr Blood Cancer. 2024 Feb 11:e30910. doi: 10.1002/pbc.30910. PMID: 38342954. Observational study. ˍ




*Castellani G, Buccarelli M, D'Alessandris QG, Ilari R, Cappannini A, Pedini F, Boe A, Lulli V, Parolini I, Giannetti S, Biffoni M, Zappavigna V, Marziali G, Pallini R, Ricci-Vitiani L.
Extracellular vesicles produced by irradiated endothelial or Glioblastoma stem cells promote tumor growth and vascularization modulating tumor microenvironment.
Cancer Cell Int. 2024 Feb 12;24(1):72. doi: 10.1186/s12935-024-03253-0. PMID: 38347567. Laboratory investigation. ˍ




Koay JM, Michaelides L, Moniz-Garcia DP, Quinones-Hinojosa A, Chaichana K, Almeida JP, Gruenbaum BF, Sherman WJ, Sabsevitz DS.
Repeated surgical resections for management of high-grade glioma and its impact on quality of life.
J Neurooncol. 2024 Feb 13. doi: 10.1007/s11060-024-04600-x. PMID: 38349476. Observational study. ˍ




Rumalla K, Thommen R, Kazim SF, Segura AC, Kassicieh AJ, Schmidt MH, Bowers CA.
Risk Analysis Index and 30-Day Mortality after Brain Tumor Resection: A Multicenter Frailty Analysis of 31,776 Patients from 2012 to 2020.
J Neurol Surg B Skull Base. 2023 Feb 13;85(2):168-171. doi: 10.1055/a-2015-1162. PMID: 38449581. Observational study. ˍ




Keeling C, Davies S, Goddard J, Ramaswamy V, Schwalbe EC, Bailey S, Hicks D, Clifford SC.
The clinical significance of sub-total surgical resection in childhood medulloblastoma: a multi-cohort analysis of 1100 patients.
EClinicalMedicine. 2024 Feb 14;69:102469. doi: 10.1016/j.eclinm.2024.102469. PMID: 38374970. Observational study. ˍ




Niitsu H, Fukumitsu N, Tanaka K, Mizumoto M, Nakai K, Matsuda M, Ishikawa E, Hatano K, Hashimoto T, Kamizawa S, Sakurai H.
Methyl-11C-L-methionine positron emission tomography for radiotherapy planning for recurrent malignant glioma.
Ann Nucl Med. 2024 Feb 14. doi: 10.1007/s12149-024-01901-z. PMID: 38356008. Observational study. ˍ




Edvardsson A, Gorgisyan J, Andersson KM, Vallhagen Dahlgren C, Dasu A, Gram D, Björk-Eriksson T, Munck Af Rosenschöld P.
Robustness and dosimetric verification of hippocampal-sparing craniospinal pencil beam scanning proton plans for pediatric medulloblastoma.
Phys Imaging Radiat Oncol. 2024 Feb 15;29:100555. doi: 10.1016/j.phro.2024.100555. PMID: 38405431. Observational study. ˍ











Topics